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Abstract
Background: Breast cancer in young Saudi women is a crucial problem. According to the 2002 annual report of
Saudi National Cancer Registry, breast cancers that developed before the age of 40 comprise 26.4% of all female
breast cancers comparing to 6.5% in the USA. Breast cancer in young patients is often associated with a poorer
prognosis, but there has been a scarcity of published data in the Middle East population.
Methods:  Total of 867 breast cancer patients seen at King Faisal Specialist Hospital & Research Centre
(KFSH&RC) between 1986 and 2002 were reviewed. Patients were divided in two age groups: ≤ 40 years and
above 40 years. The clinicopathological characteristics and treatment outcomes were compared between
younger and older age groups.
Results: Median age at presentation was 45 years. A total of 288 (33.2%) patients were aged ≤ 40 years. Hormone
receptors were positive in 69% of patients 40 and 78.2% of patients above 40 (p = 0.009). There was a significantly
higher incidence of grade III tumor in younger patients compared to older patients (p = 0.0006). Stage, tumor size,
lymphatic/vascular invasion, number of nodes and axillary lymph node status, did not differ significantly between
the two age groups. Younger patients had a greater probability of recurrence at all time periods (p = 0.035).
Young age had a negative impact on survival of patients with positive axillary lymph nodes (p = 0.030) but not on
survival of patients with negative lymph nodes (p = 0.695). Stage, tumor size, nodal status and hormonal receptors
had negative impact on survival. Adjuvant chemotherapy was administered to 87.9% of younger and 65.6% of older
patients (p < 0.0001). In terms of hormone therapy, the proportion of tamoxifen treated patients was significantly
lower in young age group (p < 0.0001). No significant difference in radiation therapy between the two groups.
Conclusion: Young age (≤ 40) is an independent risk factor for relapse in operable Saudi breast cancer patients.
The fundamental biology of young age breast cancer patients needs to be elucidated.
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Background
In Western societies, breast cancer is the most common
cancer among women and is the leading cause of cancer
mortality [1]. Breast cancer is at the top among all the
malignancies seen in Saudi females, comprising of 21.8%
[2]. In addition, breast cancer in young Saudi's women is
a crucial problem, with the proportion of young age-onset
breast cancer much higher than in western countries.
According to the 2002 annual report of Saudi national
cancer registry, breast cancers that developed before the
age 40 accounted for 26.4% of all female breast cancers
compared with only 6.5% in USA [2].
Studies have shown that the young age at diagnosis of
breast cancer is associated with a poorer prognosis [3-9] or
no impact on prognosis [10-15] than older age at diagno-
sis. Various explanations have been given to these con-
flicting results, including small numbers of patients,
differences in patient selection criteria and inconsistent
age categories used in the analyses. Indeed, it has been
reported that breast carcinoma in younger patients com-
prises substantial clinical problems. Invasive breast carci-
noma occurring in young women (defined as ages 35–40
years or younger) generally has a higher proportion of
pathological features associated with more aggressive dis-
ease (Higher proportion of late stage, positive nodes, high
grade, extensive intraductal component, presence of lym-
phatic/vascular invasion, absence of estrogen receptor,
amplification or over expression of Her2/neu gene, higher
S-phase fraction) compared to breast carcinoma occurring
in older patients [9,16-21]. There is a paucity of published
literature on experiences of treating breast cancer in a
young Middle East population. To this end, it is important
for clinicians to clarify the existing controversy as to
whether aggressive treatment for young women with
breast cancer is justified.
The aim of this study is to analyze the clinicopathological
characteristics and compare the outcomes of younger
breast cancer patients, to the older counterparts.
Methods
Patients
The pathology data and cancer registry records of the King
Faisal Specialist Hospital and Research Center
(KFSH&RC) from 1986 to 2002 were reviewed. KFSH&RC
is a tertiary care facility and serves as the main referring
center for the whole Kingdom of Saudi Arabia (KSA).
Therefore, it is conceivable that the cancer pattern seen at
KFSH&RC is a reflection to that seen in the whole country.
This study was approved by the Research Advisory Coun-
cil (Institutional Review Board) of KFSH&RC with RAC #
204006.
Only patients with stage I-III who had definitive surgery
were included. Patients with distant metastasis detected at
the time of diagnosis or within 4 months of surgery were
excluded. Patients whose surgical margins were positive
for invasive carcinoma or ductal carcinoma in situ were
also excluded. Patient's records were reviewed for the fol-
lowing: age, tumor size, histological grade (SBR: Scarff-
Bloom-Richardson classification), axillary lymph node
status, presence or absence of lymphatic/vascular inva-
sion, type of surgery and adjuvant therapy given. Estrogen
receptor (ER) and progesterone receptor (PR) were deter-
mined in over 78% of cases. Disease was staged according
to the American Joint Committee of Cancer (AJCC) sys-
tem [22]. Disease Free Survival (DFS) was calculated as
the time between diagnosis and confirmation of disease
recurrence.
Statistical analysis
Comparison of categories within a given characteristic was
carried out with the Person χ2-test and, if any of the
expected frequencies was less than five, the Fisher's exact
test was used. The disease-free survival was the time
between diagnosis and confirmation of disease recurrence
and/or death which ever comes first. Survival analysis was
conducted using Kaplan-Meier method [23], with Wil-
coxon test for statistical significance. Multivariate analyses
were carried out using Cox's proportional hazards model
[24]. Two-sided P-value of < 0.05 was considered statisti-
cally significant. All statistical analyses were performed
using SAS (version 9.1).
Results
A total of 867 patients were eligible for this study, of
which 288 (33.2%) were aged ≤ 40 at the time of diagno-
sis, and 66.8% are pre-menopausal. The median age of the
patients was 45 years (range 14 – 90 years). The median
tumor size was 3.0 cm (range 1 – 29.0 cm). The histology
data showed that the distribution of invasive ductal carci-
noma, compared to lobular carcinoma, was significantly
higher in the younger age group compared to older age
group (p = 0.0009). There was a higher proportion of dou-
ble negative ER/PR status in the younger age group (p =
0.0086). In addition, there was a significant difference in
the grade between the two groups; Grade III tumors con-
stituted 48.5% and 36.4% of cases for patients ≤ 40 and >
40 years of age respectively. Axillary lymph node status,
the most prominent prognostic factor in breast cancer,
was not significantly different between the two groups. In
addition, neither the tumor size, stage, lymph-lymphatic/
vascular invasion nor numbers of nodes were different
between the two groups. The clinicopathological charac-
teristics of the patients in the two age groups are shown in
Table 1.BMC Cancer 2007, 7:222 http://www.biomedcentral.com/1471-2407/7/222
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Table 2 shows the data obtained for the different thera-
peutic treatments of the 2 age groups. The proportion of
breast-conserving surgery compared to mastectomy was
significantly different between the two age groups (p =
0.0006). Adjuvant chemotherapy was administered to
87.9% of younger and 65.6% of older patients (p  <
0.0001). In terms of hormone therapy, the proportion of
tamoxifen treated patients was significantly lower in
young age group (p < 0.0001). Adjuvant radiation therapy
was administered to patients who underwent breast-con-
serving surgery and after mastectomy in patients who had
four or more positive lymph nodes or a tumor size > 5 cm
in diameter. No significant difference in radiation therapy
between the two groups.
Overall, the 5- and 10-year disease-free survival (DFS) of
the study population was 82% and 66%, respectively.
When we stratified patients by age groups, DFS was signif-
icantly poorer for the younger group (Figure 1; p = 0.035).
Ten-year DFS of younger patients (≤ 40 years) was 60%,
compared to 70% for older patients over 40 years. Tumor
size, nodal involvement, number of positive nodes, path-
ological stages, grade, hormonal receptor status, and lym-
phatic/vascular invasion were significant prognostic
discriminate of DFS (Table 3).
Stratified analysis according to axillary lymph node status
was performed. In lymph node-positive patients there was
a significant difference in DFS between the two age groups
(Figure 2; p = 0.030). However, in lymph node-negative
patients, DFS was not significant (p = 0.695).
In multivariate analysis, young age (≤ 40 years) remained
a significant predictor of relapse when entered into a
model containing all potential demographic, pathologic
and immunohistochemical variables (Table 4. Hazard
Ratio (HR), 1.5; confidence interval, 1.0 – 2.2; p  =
0.0352).
Discussion
Patients included in this study illustrate interesting char-
acteristics where 33.2% are young (≤ 40 years) and 66.8%
are pre-menopausal. While the median age at presenta-
tion is around 63 years in the United States and Western
Table 1: Clinical and pathological characteristics of all patients grouped as 40 years and > 40 years old
Characteristics Age (years) P-value Total (unknown)
≤ 40 n (%) > 40 n (%)
Node Status 838
Positive 159 (57.8) 320 (56.8) 0.7878 (29)
Negative 116 (42.2) 243 (43.2)
Tumor Size 824
≤ 2 93 (32.3) 186 (32.1) (43)
3 – 5 155 (53.8)) 320 (55.3) 0.8532
≤ 5 40 (13.9) 73 (12.6)
Number of Nodes 824
0 116 (42.3) 241 (43.1) (43)
1 – 3 83 (30.3) 178 (31.8) 0.6731
4 – 10 51 (18.6) 104 (18.6)
> 10 24 (8.8) 36 (6.4)
Stage 762
I 38 (15.0) 67 (13.1) (105)
II 170 (67.5) 347 (68.1) 0.7259
III 44 (17.5) 96 (18.8)
Grade 793
I 7 (2.6) 38 (7.2) (74)
II 130 (48.9) 297 (56.4) 0.0006
III 129 (48.5) 192 (36.4)
Histopathology 854
(13)
Infiltrating ductal 270 (98.5) 520 (93.2) 0.0009
Infiltrating lobular 4 (1.5) 38 (6.8)
Lymph-Vascular Invasion 702
Both Positive 84 (36.7) 159 (33.8) 0.4459 (165)
Both Negative 145 (63.3) 312 (66.2)
Hormonal Receptor Status 677
ER+ PR+ 99 (44.6) 252 (55.4) 0.0086 (190)
ER- PR- 69 (31.1) 99 (21.8)
ER+ PR- 13 (5.9) 39 (8.6)
ER- PR+ 41 (18.5) 65 (14.3)BMC Cancer 2007, 7:222 http://www.biomedcentral.com/1471-2407/7/222
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Europe, the median age at presentation in this study is 45
years. The young age of patients in this study is attributed
to the overall age distribution in the KSA, where 50% of
the population is less than 15 years of age and only 3% are
older than 65 years. These patients' characteristics are in
sharp contrast with those reported in the West.
Gajdos et al [25] reported that patients diagnosed with
breast cancer before age 36 differ from older patients in
several respects. The younger age group presents more
often with more advanced and aggressive cancer. In spite
of aggressive treatment (mastectomy and chemotherapy)
in the younger age group, local and distant failure rates are
higher than for patients 36 and older. The higher rate of
local recurrence in patients less than 36 years reflects an
excess number of local recurrences in patients treated with
breast conservation. In the present study, we have found
that patients ≤ 40 years were treated more often with
breast-conserving surgery compared to mastectomy
(48.6% versus 36.5%, p = 0.0006), adjuvant chemother-
apy (87.9% versus 65.6%, p < 0.0001), and less often with
tamoxifen (p < 0.0001). Our current findings are in agree-
ment with what have been reported by Gajdos et al inves-
tigating breast cancer in young women [25]. It is
important to mention that similar protocols for the treat-
ment of breast cancer patients were used in both USA and
KSA and this may reflect the similarity of both studies.
Our results show that young age is a critical prognostic
factor in women with breast cancer in Saudi Arabia.
Among all studied prognostic factors, the distribution of
grade, histology, and hormonal receptor status showed a
Stratified analysis of survival of breast cancer between the two age groups (≤ 40, and above 40): Patients with operable breast  cancer below the age of 40 had a worse survival than the group above age 40 Figure 1
Stratified analysis of survival of breast cancer between the two age groups (≤ 40, and above 40): Patients with operable breast 
cancer below the age of 40 had a worse survival than the group above age 40.BMC Cancer 2007, 7:222 http://www.biomedcentral.com/1471-2407/7/222
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significant difference between the two age groups in our
patient population.
The results of the present investigation showed that being
young age at diagnosis (≤ 40 years) is an independent
prognostic factor for disease-free survival in addition to
nodal status, pathological tumor size, stage and hormonal
receptor status. We performed subgroup analysis by inves-
tigating patients with negative versus positive lymph
nodes and had different results. Young age had a signifi-
cant impact on survival in patients with positive lymph
nodes but not in patients with negative lymph nodes.
Table 3: Kaplan-Meier estimates of 5-year disease-free survival in relation to tumor and patient characteristics
Characteristics Number Patients 5-year Survival Rate 95% CI P-value
Age 0.0353
≤ 40 288 0.7740 0.7201 – 0.8279
> 40 579 0.8346 0.8007 – 0.8685
Node Status
• Positive 479 0.7667 0.7240 – 0.8094 < 0.0001
• Negative 359 0.8957 0.8608 – 0.9306
Tumor Size
≤ 2 279 0.8534 0.8062 – 0.9006 0.0052
3 – 5 475 0.8205 0.7823 – 0.8587
> 5 113 0.7021 0.6090 – 0.7952
Number of Nodes
0 357 0.8953 0.8604 – 0.9302 < 0.0001
1 – 3 261 0.8057 0.7524 – 0.8590
4 – 10 155 0.7624 0.6850 – 0.8398
> 10 60 0.5553 0.3969 – 0.7137
Stage
I 105 0.8881 0.8220 – 0.9542 0.0252
II 512 0.8307 0.7954 – 0.8660
III 140 0.7531 0.6731 – 0.8331
Grade 0.0109
I 45 0.9750 0.9266 – 1.0000
II 427 0.8290 0.7890 – 0.8690
III 321 0.7681 0.7171 – 0.8191
Histo-pathology
• Infiltrating ductal 780 0.8145 0.7861 – 0.8429 0.2180
• Infiltrating lobular 42 0.8682 0.7404 – 0.9960
Lymphatic/Vascular 
Invasion
242 0.7458 0.6835 – 0.8081 0.0002




• ER+ PR+ 351 0.8425 0.7960 – 0.8890 0.0069
• ER- PR- 168 0.7942 0.7266 – 0.8618
• ER+ PR- 52 0.7866 0.6688 – 0.9044
• ER- PR+ 106 0.7113 0.6000 – 0.8226
Table 2: Treatment characteristics
Treatments Age (years) P-value
≤ 40 n (%) > 40
Adjuvant Anthracycline 210 (87.9) 330 (65.6) < 0.0001
Surgery
• Mastectomy 148 (51.4) 367 (63.5) 0.0006
• Breast conservation 140 (48.6) 211 (36.5)
Adjuvant radiotherapy 245 (85.1) 470 (81.2) 0.1554
Adjuvant hormonal therapy 146 (58.4) 434 (81.4) < 0.0001BMC Cancer 2007, 7:222 http://www.biomedcentral.com/1471-2407/7/222
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The present findings support previous reports showing
that women diagnosed with breast cancer at younger age
have a poorer prognosis compared with their older coun-
terparts [8,18,26-28]. The extensive heterogeneity of
breast cancer complicates the precise assessment of tumor
aggressiveness which makes therapeutic decisions difficult
and treatment impropriate in some cases [28]. Therefore,
it is very important to understand the interactions
between the genetic complexity and the environmental
factors which modulate the onset and progression of
breast cancer in young women which may help in design-
ing a personalized treatment for this patient population.
For example, it has been demonstrated that about 15–
30% of western breast cancer women aged less than 35
years are likely to have germ-line BRCA1 or BRCA2 muta-
tions [29,30]. Similar results were reported for BRCA1 and
BRCA2 mutations in Korean women with breast cancer at
a young age (< 40 years) [31] and also for BRCA1 muta-
tions in a series of Singaporean Chinese women with early
onset (cut-off of 40 years) [32]. Study on BRCA1 and
BRCA2 mutations in Saudi women older than 40 years
with breast cancer concluded that mutations in these
genes are likely to contribute to the pathogenesis of famil-
ial breast cancer in the Kingdom of Saudi Arabia [33]. A
recent interesting tissue microarray study by Eerola et al
[34]demonstrated that tumors of BRCA1 and BRCA2 pos-
itive-mutations aged 50 years or more (postmenopausal)
differed significantly from those of younger age group
(premenopausal) with similar mutations. This difference
may reflect diverse biological behavior and pathways of
tumor development among the older and the younger
BRCA1 and BRCA2 patients, with impact also on progno-
Kaplan-Meier survival analysis of patients with positive axillary lymph nodes and effects on survival stratified by age groups ≤ 40  years, and above 40 years Figure 2
Kaplan-Meier survival analysis of patients with positive axillary lymph nodes and effects on survival stratified by age groups ≤ 40 
years, and above 40 years. Patients with positive axillary lymph nodes and young age have worst survival. (P = 0.030).BMC Cancer 2007, 7:222 http://www.biomedcentral.com/1471-2407/7/222
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sis and survival. Overall, there is an emerging picture indi-
cating that breast cancer risk in BRCA1 and BRCA2
positive women are substantially higher than in the gen-
eral population and the genes are considerably affected by
non-genetic, environmental factors and by additional
genetic modifiers [35]. In the light of the high incidence
of breast cancer in young Saudi women [2], mutation
study of these genes and gene-expression profile, which is
a more powerful predictor of the outcome of disease in
young patients with breast cancer [36], are extremely war-
ranted.
Conclusion
In conclusion, we show that operable Saudi young breast
cancer patients (≤ 40 years old) have a worse prognosis
than older patients. Increasing tumor size, late stage, pos-
itive lymph nodes, young age at diagnosis, and hormonal
receptor status were independent prognostic indicator for
survival. Indeed younger patients have a poorer disease
free survival. The underlying biology of breast cancer
among patients needs to be elucidated.
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